Hekmat B Khoukaz1, Yan Ji1, Drew J Braet1, Manisha Vadali1, Ahmed A Abdelhamid1, Cory D Emal2, Daniel A Lawrence3, William P Fay1,4,5. 1. From the Department of Medicine (H.B.K, Y.J., D.J.B., M.V., A.A.A., W.P.F.), University of Missouri School of Medicine. 2. Department of Chemistry, Eastern Michigan University, Ypsilanti (C.D.E.). 3. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor (D.A.L.). 4. Department of Medical Pharmacology & Physiology (W.P.F.), University of Missouri School of Medicine. 5. Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO (W.P.F.).
Abstract
OBJECTIVE: Enhanced expression of PAI-1 (plasminogen activator inhibitor-1) has been implicated in atherosclerosis formation in humans with obesity and metabolic syndrome. However, little is known about the effects of pharmacological targeting of PAI-1 on atherogenesis. This study examined the effects of pharmacological PAI-1 inhibition on atherosclerosis formation in a murine model of obesity and metabolic syndrome. Approach and Results: LDL receptor-deficient (ldlr-/-) mice were fed a Western diet high in cholesterol, fat, and sucrose to induce obesity, metabolic dysfunction, and atherosclerosis. Western diet triggered significant upregulation of PAI-1 expression compared with normal diet controls. Addition of a pharmacological PAI-1 inhibitor (either PAI-039 or MDI-2268) to Western diet significantly inhibited obesity and atherosclerosis formation for up to 24 weeks without attenuating food consumption. Pharmacological PAI-1 inhibition significantly decreased macrophage accumulation and cell senescence in atherosclerotic plaques. Recombinant PAI-1 stimulated smooth muscle cell senescence, whereas a PAI-1 mutant defective in LRP1 (LDL receptor-related protein 1) binding did not. The prosenescent effect of PAI-1 was blocked by PAI-039 and R2629, a specific anti-LRP1 antibody. PAI-039 significantly decreased visceral adipose tissue inflammation, hyperglycemia, and hepatic triglyceride content without altering plasma lipid profiles. CONCLUSIONS: Pharmacological targeting of PAI-1 inhibits atherosclerosis in mice with obesity and metabolic syndrome, while inhibiting macrophage accumulation and cell senescence in atherosclerotic plaques, as well as obesity-associated metabolic dysfunction. PAI-1 induces senescence of smooth muscle cells in an LRP1-dependent manner. These results help to define the role of PAI-1 in atherosclerosis formation and suggest a new plasma-lipid-independent strategy for inhibiting atherogenesis.
OBJECTIVE: Enhanced expression of PAI-1 (plasminogen activator inhibitor-1) has been implicated in atherosclerosis formation in humans with obesity and metabolic syndrome. However, little is known about the effects of pharmacological targeting of PAI-1 on atherogenesis. This study examined the effects of pharmacological PAI-1 inhibition on atherosclerosis formation in a murine model of obesity and metabolic syndrome. Approach and Results:LDL receptor-deficient (ldlr-/-) mice were fed a Western diet high in cholesterol, fat, and sucrose to induce obesity, metabolic dysfunction, and atherosclerosis. Western diet triggered significant upregulation of PAI-1 expression compared with normal diet controls. Addition of a pharmacological PAI-1 inhibitor (either PAI-039 or MDI-2268) to Western diet significantly inhibited obesity and atherosclerosis formation for up to 24 weeks without attenuating food consumption. Pharmacological PAI-1 inhibition significantly decreased macrophage accumulation and cell senescence in atherosclerotic plaques. Recombinant PAI-1 stimulated smooth muscle cell senescence, whereas a PAI-1 mutant defective in LRP1 (LDL receptor-related protein 1) binding did not. The prosenescent effect of PAI-1 was blocked by PAI-039 and R2629, a specific anti-LRP1 antibody. PAI-039 significantly decreased visceral adipose tissue inflammation, hyperglycemia, and hepatic triglyceride content without altering plasma lipid profiles. CONCLUSIONS: Pharmacological targeting of PAI-1 inhibits atherosclerosis in mice with obesity and metabolic syndrome, while inhibiting macrophage accumulation and cell senescence in atherosclerotic plaques, as well as obesity-associated metabolic dysfunction. PAI-1 induces senescence of smooth muscle cells in an LRP1-dependent manner. These results help to define the role of PAI-1 in atherosclerosis formation and suggest a new plasma-lipid-independent strategy for inhibiting atherogenesis.
Authors: Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence Journal: J Biol Chem Date: 2018-12-03 Impact factor: 5.157
Authors: Aernout Luttun; Florea Lupu; Erik Storkebaum; Marc F Hoylaerts; Lieve Moons; James Crawley; Françoise Bono; A Robin Poole; Peter Tipping; Jean-Marc Herbert; Désiré Collen; Peter Carmeliet Journal: Arterioscler Thromb Vasc Biol Date: 2002-03-01 Impact factor: 8.311
Authors: Eddy S Konaniah; David G Kuhel; Joshua E Basford; Neal L Weintraub; David Y Hui Journal: Arterioscler Thromb Vasc Biol Date: 2017-05-04 Impact factor: 8.311
Authors: Bennett G Childs; Darren J Baker; Tobias Wijshake; Cheryl A Conover; Judith Campisi; Jan M van Deursen Journal: Science Date: 2016-10-27 Impact factor: 47.728
Authors: Alec D Weisberg; Francisco Albornoz; Jane P Griffin; David L Crandall; Hassan Elokdah; Agnes B Fogo; Douglas E Vaughan; Nancy J Brown Journal: Arterioscler Thromb Vasc Biol Date: 2004-12-02 Impact factor: 8.311
Authors: Mesut Eren; Amanda E Boe; Sheila B Murphy; Aaron T Place; Varun Nagpal; Luisa Morales-Nebreda; Daniela Urich; Susan E Quaggin; G R Scott Budinger; Gökhan M Mutlu; Toshio Miyata; Douglas E Vaughan Journal: Proc Natl Acad Sci U S A Date: 2014-04-28 Impact factor: 11.205
Authors: Mary Migliorini; Shih-Hon Li; Anqi Zhou; Cory D Emal; Daniel A Lawrence; Dudley K Strickland Journal: J Biol Chem Date: 2019-12-02 Impact factor: 5.157
Authors: Joshua A Levine; Shantel Olivares; Toshio Miyata; Douglas E Vaughan; Anne S Henkel Journal: Obesity (Silver Spring) Date: 2021-02-16 Impact factor: 5.002